Liquidia Co. (NASDAQ:LQDA - Get Free Report) insider Rajeev Saggar sold 2,450 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $13.67, for a total transaction of $33,491.50. Following the transaction, the insider now owns 263,152 shares in the company, valued at $3,597,287.84. This trade represents a 0.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Liquidia Trading Up 0.4 %
LQDA opened at $13.55 on Thursday. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -8.31 and a beta of 0.23. Liquidia Co. has a 12-month low of $8.26 and a 12-month high of $16.81. The business's fifty day simple moving average is $14.49 and its 200-day simple moving average is $12.85.
Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The business had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. On average, equities research analysts predict that Liquidia Co. will post -1.51 EPS for the current year.
Analyst Ratings Changes
A number of research analysts have recently commented on LQDA shares. HC Wainwright reaffirmed a "buy" rating and set a $29.00 target price on shares of Liquidia in a research note on Thursday, March 20th. Scotiabank reaffirmed an "outperform" rating on shares of Liquidia in a research report on Thursday, March 20th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $25.00 target price on shares of Liquidia in a research report on Thursday, April 10th. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Liquidia currently has an average rating of "Buy" and a consensus target price of $26.63.
Check Out Our Latest Research Report on LQDA
Hedge Funds Weigh In On Liquidia
Several institutional investors have recently bought and sold shares of LQDA. GAMMA Investing LLC boosted its position in Liquidia by 65.6% during the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock valued at $44,000 after acquiring an additional 1,173 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new position in shares of Liquidia in the 4th quarter worth $59,000. Summit Investment Advisors Inc. lifted its stake in shares of Liquidia by 35.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after purchasing an additional 1,719 shares during the last quarter. D. E. Shaw & Co. Inc. bought a new stake in Liquidia during the fourth quarter valued at about $142,000. Finally, EntryPoint Capital LLC purchased a new position in Liquidia in the fourth quarter valued at about $154,000. 64.54% of the stock is owned by hedge funds and other institutional investors.
Liquidia Company Profile
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
